Drug intelligence / Profile preview

Difrarel

Development stage: Unknown
Lead developer: Théa Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Difrarel is a pharmaceutical product containing procyanidolic oligomers (OPCs), which are natural plant-derived compounds known for their antioxidant and vasoprotective properties. It is primarily indicated for the treatment of microvascular complications, specifically diabetic retinopathy. The drug works by increasing capillary resistance and decreasing permeability, thereby protecting the retinal vasculature from damage associated with chronic hyperglycemia and oxidative stress. In the Chinese market, it is distributed by Huizhou Baijirui, which serves as an agency for the original French manufacturer, Laboratoires Théa.

Brand names: Difrarel
Other names: procyanidolic oligomersOPC

Beyond the preview

Go deeper on Difrarel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Difrarel.

Explore the full profile